Antibody Developer Taken Out by Gilead at 'Hefty Premium'
Source: Streetwise Reports  (3/4/20)
The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. More >

Digital Health Firm to Place Telemedicine Kiosks in Pharmacy Consult Rooms
Source: Streetwise Reports  (3/4/20)
CloudMD announced it will be installing proprietary kiosks in participating pharmacies to enable on-demand telemedicine visits with licensed physicians. More >

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data
Source: Streetwise Reports  (3/4/20)
Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. More >

Telemedicine Platform Provider for Community-Based Healthcare Adds 50,000 Medicare Members
Source: Streetwise Reports  (3/3/20)
Reliq Health Technologies reported that it has signed a contract with Blum Telehealth to provide its iUGO Care software platform to over 50,000 Medicare patients in the state of Louisiana. More >

GenMark Shares Trade 30% Higher on Yearly Earnings and Increased SARS-CoV-2 Virus Detection Test Kit Shipments
Source: Streetwise Reports  (3/3/20)
Shares of GenMark Diagnostics traded higher after the firm reported FY/19 financial results and announced that it has increased global shipment of its test kits designed to detect the SARS-CoV-2 virus. More >

Digital Health Firm Scales Up Telemedicine Services as Global Coronavirus Concerns Mount
Source: Streetwise Reports  (3/2/20)
CloudMD will be scaling up its freely accessible telemedicine app that allows patients to see a doctor in real-time using either a smartphone or desktop device. More >

Health Tech Firm to Service Sizable Home Healthcare Network
Source: Streetwise Reports  (3/2/20)
Reliq Health Technologies will provide its software and call center support. More >

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results
Source: Streetwise Reports  (3/2/20)
Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. More >

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration
Source: Streetwise Reports  (2/28/20)
Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases. More >

Teladoc Shares Trade 20% Higher on Virtual Medicine Tailwinds and Q4 Earnings
Source: Streetwise Reports  (2/27/20)
Shares of Teladoc Health climbed to a new 52-week high price after the firm reported Q4/19 and FY/19 financial results that included a 32% year-over-year increase in revenue and a 57% increase in patient visits. More >

Nemaura Medical Accelerates Launch of sugarBEAT Wearable Continuous Glucose Monitor
Source: Streetwise Reports  (2/26/20)
Shares of Nemaura Medical traded 20% higher after the firm reported that it is investigating using its non-invasive continuous glucose monitor sugarBEAT® jointly with its planned health subscription service BEAT®diabetes, to provide personalized lifestyle coaching for people with Type 2 diabetes and prediabetes. More >

Mobile Health and Telemedicine Provider for Community-Based Healthcare Teams Up with US Health Data Firm
Source: Streetwise Reports  (2/26/20)
Reliq Health Technologies advised that it has been selected as remote patient monitoring and chronic care management solutions partner by U.S. health data company MaxMD. More >

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study
Source: Streetwise Reports  (2/25/20)
Shares of Moderna traded 23% higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. More >

Two Stock-Moving Catalysts Expected in March for Biopharma
Source: Streetwise Reports  (2/25/20)
These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. More >

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial
Source: Streetwise Reports  (2/24/20)
Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. More >

Antibiotic-Free Feed Additive Shows Benefit in Cow Mastitis Trial
Source: Streetwise Reports  (2/24/20)
Avivagen's proprietary product yielded statistically significant results. More >

Healthcare Tech Firm Lands Contract in Florida
Source: Streetwise Reports  (2/22/20)
Reliq Health Technologies will provide the client with two telehealth platforms. More >

Tech Firm Announces New Deals Worth $1 Million
Source: Streetwise Reports  (2/21/20)
These newly signed contracts of HealthSpace Data Systems are with governmental agencies in two U.S. states. More >

Mobile/Telehealth Tech Firm Makes Stock Exchange's Top 10
Source: Streetwise Reports  (2/21/20)
Reliq Health Technologies is chosen based on three criteria. More >

Healthcare Firm Changes Name to Reflect Digital Health and Telemedicine Focus
Source: Streetwise Reports  (2/21/20)
Premier Health Group announced that it changed its name to CloudMD Software & Services Inc., and trading under the symbol DOC will begin Feb. 24. More >

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication
Source: Streetwise Reports  (2/21/20)
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESOâ„¢ drug for management of moderate to severe pain. More >

FDA Approval of Biopharma's Pain Drug Expected This Year
Source: Streetwise Reports  (2/19/20)
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. More >

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens
Source: Fincom Investment Partners for Streetwise Reports  (2/18/20)
Fincom Investment Partners profiles TOMI Environmental Solutions, whose SteraMist disinfectant technology kills the coronavirus. More >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation
Source: Streetwise Reports  (2/18/20)
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. More >

Life Sciences Firm Contracts with Philippines Distributor
Source: Streetwise Reports  (2/18/20)
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. More >